Lv21
116 积分 2021-04-20 加入
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
6小时前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
7小时前
已完结
Silent mutations make noise
28天前
已完结
乳腺癌HER2检测指南（2024版）
2个月前
已完结
人表皮生长因子受体 2 低表达乳腺癌 临床诊疗共识 (2022 版)
7个月前
已完结
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
8个月前
已完结
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
8个月前
已完结
神经内镜经鼻蝶入路切除颅底脊索瘤的临床疗效及其影响因素分析
10个月前
已完结
颈椎脊索瘤无复发生存率的影响因素及预测模型
10个月前
已完结
颅底脊索瘤原发和局部复发阶段的病理学变化特点及其预后意义
10个月前
已完结
皖公网安备34019202002308
